Strategic objectives

• To advance the pathophysiological understanding of ischemia-reperfusion injury in the context of kidney transplantation through translational research from the experimental to the clinical setting.
• To identify biomarkers that predict graft viability and function after kidney transplantation.
• To advance the development of models for pharmacological modulation of ischemia-reperfusion injury during kidney preservation in perfusion devices.
• To evaluate the diagnostic yield and therapeutic efficacy of new diagnostic and treatment techniques for prostate cancer: MRI fusion biopsy and ultrasound using guided navigation systems, focal prostate cancer ablation techniques, and intraoperative neurostimulation of neurovascular bundles in prostate surgery.
• To actively participate in multicenter studies evaluating new molecules for the treatment of prostate cancer.
• To actively participate in multicenter studies and cooperative groups for the study and treatment of functional and oncological bladder pathology.
• To search for biomarkers that predict treatment response and disease recurrence, as well as to molecularly characterize the neoplasia and tumor microenvironment in renal and urothelial cancer.

Research lines

• Kidney transplantation and preservation in experimental and clinical settings.
• Prostate cancer: diagnostic and therapeutic innovation.
• Diagnostic and therapeutic innovation in bladder pathology.
• Diagnostic and therapeutic innovation in renal and urothelial tumors.